These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

86 related articles for article (PubMed ID: 10423161)

  • 1. Drug uptake and cellular targets of hydroxymethylacylfulvene (HMAF).
    Herzig MC; Arnett B; MacDonald JR; Woynarowski JM
    Biochem Pharmacol; 1999 Jul; 58(2):217-25. PubMed ID: 10423161
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Differential cytotoxicity and induction of apoptosis in tumor and normal cells by hydroxymethylacylfulvene (HMAF).
    Woynarowska BA; Woynarowski JM; Herzig MC; Roberts K; Higdon AL; MacDonald JR
    Biochem Pharmacol; 2000 May; 59(10):1217-26. PubMed ID: 10736422
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects on DNA integrity and apoptosis induction by a novel antitumor sesquiterpene drug, 6-hydroxymethylacylfulvene (HMAF, MGI 114).
    Woynarowski JM; Napier C; Koester SK; Chen SF; Troyer D; Chapman W; MacDonald JR
    Biochem Pharmacol; 1997 Dec; 54(11):1181-93. PubMed ID: 9416969
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antitumor activity of MGI 114 (6-hydroxymethylacylfulvene, HMAF), a semisynthetic derivative of illudin S, against adult and pediatric human tumor colony-forming units.
    Hidalgo M; Izbicka E; Eckhardt SG; MacDonald JR; Cerna C; Gomez L; Rowinsky EK; Weitman SD; Von Hoff DD
    Anticancer Drugs; 1999 Oct; 10(9):837-44. PubMed ID: 10587294
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting apoptosis by hydroxymethylacylfulvene in combination with gamma radiation in prostate tumor cells.
    Woynarowska BA; Roberts K; Woynarowski JM; MacDonald JR; Herman TS
    Radiat Res; 2000 Oct; 154(4):429-38. PubMed ID: 11023607
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterization of MGI 114 (HMAF) histiospecific toxicity in human tumor cell lines.
    Kelner MJ; McMorris TC; Montoya MA; Estes L; Uglik SF; Rutherford M; Samson KM; Bagnell RD; Taetle R
    Cancer Chemother Pharmacol; 1999; 44(3):235-40. PubMed ID: 10453725
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of HMAF (MGI-114) in the MV522 metastatic lung carcinoma xenograft model nonresponsive to traditional anticancer agents.
    Kelner MJ; McMorris TC; Estes L; Wang W; Samson KM; Taetle R
    Invest New Drugs; 1996; 14(2):161-7. PubMed ID: 8913837
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-leukemic action of the novel agent MGI 114 (HMAF) and synergistic action with topotecan.
    Kelner MJ; McMorris TC; Estes L; Samson KM; Trani NA; MacDonald JR
    Leukemia; 2000 Jan; 14(1):136-41. PubMed ID: 10637489
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Up-regulation of human prostaglandin reductase 1 improves the efficacy of hydroxymethylacylfulvene, an antitumor chemotherapeutic agent.
    Yu X; Erzinger MM; Pietsch KE; Cervoni-Curet FN; Whang J; Niederhuber J; Sturla SJ
    J Pharmacol Exp Ther; 2012 Nov; 343(2):426-33. PubMed ID: 22895897
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of antidotes for extravasation injury produced by 6-hydroxymethylacylfulvene (MGI 114), a novel cytotoxic antitumor agent, in an intradermal toxicity model in rats.
    Marshall RF; Arthaud LE; MacDonald JR
    Cancer Chemother Pharmacol; 2000; 45(5):397-401. PubMed ID: 10803923
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Determination of covalent binding to intact DNA, RNA, and oligonucleotides by intercalating anticancer drugs using high-performance liquid chromatography. Studies with doxorubicin and NADPH cytochrome P-450 reductase.
    Cummings J; Bartoszek A; Smyth JF
    Anal Biochem; 1991 Apr; 194(1):146-55. PubMed ID: 1714250
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Apoptosis induction by the dual-action DNA- and protein-reactive antitumor drug irofulven is largely Bcl-2-independent.
    Herzig MC; Trevino AV; Liang H; Salinas R; Waters SJ; MacDonald JR; Woynarowska BA; Woynarowski JM
    Biochem Pharmacol; 2003 Feb; 65(4):503-13. PubMed ID: 12566077
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preclinical antitumor activity of 6-hydroxymethylacylfulvene, a semisynthetic derivative of the mushroom toxin illudin S.
    MacDonald JR; Muscoplat CC; Dexter DL; Mangold GL; Chen SF; Kelner MJ; McMorris TC; Von Hoff DD
    Cancer Res; 1997 Jan; 57(2):279-83. PubMed ID: 9000568
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery and development of sesquiterpenoid derived hydroxymethylacylfulvene: a new anticancer drug.
    McMorris TC
    Bioorg Med Chem; 1999 May; 7(5):881-6. PubMed ID: 10400341
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Selective cellular uptake and retention of SN 28049, a new DNA-binding topoisomerase II-directed antitumor agent.
    Chen YY; Lukka PB; Joseph WR; Finlay GJ; Paxton JW; McKeage MJ; Baguley BC
    Cancer Chemother Pharmacol; 2014 Jul; 74(1):25-35. PubMed ID: 24801172
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Metabolism of antitumor hydroxymethylacylfulvene by rat liver cytosol.
    McMorris TC; Elayadi AN; Yu J; Hu Y; Kelner MJ
    Drug Metab Dispos; 1999 Sep; 27(9):983-5. PubMed ID: 10460795
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Promising new agents for treatment of patients with colorectal cancer.
    Von Hoff DD
    Semin Oncol; 1998 Oct; 25(5 Suppl 11):47-52. PubMed ID: 9786316
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Binding of the epoxide cryptophycin analog, LY355703 to albumin and its effect on in vitro antiproliferative activity.
    Schultz RM; Shih C; Wood PG; Harrison SD; Ehlhardt WJ
    Oncol Rep; 1998; 5(5):1089-94. PubMed ID: 9683814
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A cellular mechanism for imidocarb retention in edible bovine tissues.
    Moore AS; Coldham NG; Sauer MJ
    Toxicol Lett; 1996 Oct; 87(2-3):61-8. PubMed ID: 8914612
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Depurinating acylfulvene-DNA adducts: characterizing cellular chemical reactions of a selective antitumor agent.
    Gong J; Vaidyanathan VG; Yu X; Kensler TW; Peterson LA; Sturla SJ
    J Am Chem Soc; 2007 Feb; 129(7):2101-11. PubMed ID: 17256933
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.